NICE Technology Appraisals

Spesolimab GPP flare prevention appraisal terminated, no evidence

NICE has terminated its appraisal of subcutaneous spesolimab (Spevigo) 1-ml formulation for preventing generalized pustular psoriasis flares in patients 12 years and older. The termination occurred because the manufacturer did not provide an evidence submission, leaving NICE unable to assess clinical effectiveness or cost-effectiveness. No NHS funding guidance will be issued for this indication.

Fezolinetant (Veoza) for Menopause Vasomotor Symptoms

NICE published technology appraisal guidance TA1143 recommending fezolinetant (Veoza) as an option for treating moderate to severe vasomotor symptoms associated with menopause. The guidance applies to women who have had a breast cancer diagnosis where hormone replacement therapy is contraindicated. NHS commissioners must make funding available within 3 months of publication date.

Dupilumab for Uncontrolled COPD with Raised Eosinophils

NICE has issued technology appraisal guidance TA1142 recommending dupilumab (Dupixent) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) and raised blood eosinophils. The guidance provides evidence-based recommendations for healthcare professionals.

Ruxolitinib cream for non-segmental vitiligo in people 12+

NICE has published updated technology appraisal guidance (TA1140) on ruxolitinib cream for treating non-segmental vitiligo in individuals aged 12 and over. This guidance replaces previous recommendations and includes information on commercial arrangements for the drug.

Nivolumab for Urothelial Cancer Appraisal Terminated

NICE has terminated the appraisal of nivolumab for urothelial cancer because the company failed to submit evidence. The guidance will be reviewed if the company decides to make a submission in the future.

NICE Guidance: Epcoritamab for Follicular Lymphoma

NICE has published technology appraisal guidance (TA1139) recommending epcoritamab (Tepkinly) for treating relapsed or refractory follicular lymphoma in adults after two or more lines of systemic treatment. The guidance outlines evidence-based recommendations for healthcare professionals.

NICE Guidance: Durvalumab for Muscle-Invasive Bladder Cancer

NICE has published technology appraisal guidance (TA1138) recommending durvalumab with gemcitabine and cisplatin for the neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer. The guidance includes information on commercial arrangements and reporting adverse events.

Baloxavir marboxil appraisal terminated for children

NICE has terminated the appraisal of baloxavir marboxil for treating and preventing influenza in children aged 1 to 11 years. The decision was made because the company failed to provide an evidence submission for the technology appraisal.

NICE Guidance on Bevacizumab for Metastatic Colorectal Cancer (TA1136)

NICE has published updated technology appraisal guidance (TA1136) on the use of bevacizumab (originator and biosimilars) with fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. This guidance replaces previous recommendations and provides evidence-based recommendations for healthcare professionals.

Canagliflozin Appraisal Terminated for Type 2 Diabetes in Youth

NICE has terminated the appraisal of canagliflozin (Invokana) for treating type 2 diabetes in individuals aged 10 to 17 years. The appraisal was terminated because the company failed to provide an evidence submission. NICE will review this decision if a submission is made.